[go: up one dir, main page]

MX2013011174A - Prevencion de hipoglucemia en pacientes con diabetes sacarina de tipo 2. - Google Patents

Prevencion de hipoglucemia en pacientes con diabetes sacarina de tipo 2.

Info

Publication number
MX2013011174A
MX2013011174A MX2013011174A MX2013011174A MX2013011174A MX 2013011174 A MX2013011174 A MX 2013011174A MX 2013011174 A MX2013011174 A MX 2013011174A MX 2013011174 A MX2013011174 A MX 2013011174A MX 2013011174 A MX2013011174 A MX 2013011174A
Authority
MX
Mexico
Prior art keywords
pharmaceutically acceptable
acceptable salt
hypoglycaemia
prevention
diabetes mellitus
Prior art date
Application number
MX2013011174A
Other languages
English (en)
Other versions
MX336657B (es
Inventor
Gabor Boka
Louise Silvestre
Patrick Miossec
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44504331&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2013011174(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of MX2013011174A publication Critical patent/MX2013011174A/es
Publication of MX336657B publication Critical patent/MX336657B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)

Abstract

Un método para la prevención de hipoglucemia en diabetes sacarina de tipo 2 que comprende administrar (a) desPro36-exendina-4(1-39)- Lys6-NH2 y/o una sal farmacéuticamente aceptable de la misma y (b) una sulfonilurea y/o una sal farmacéuticamente aceptable de la misma a un sujeto necesitado de ello.
MX2013011174A 2011-03-29 2012-03-29 Prevencion de hipoglucemia en pacientes con diabetes sacarina de tipo 2. MX336657B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11160270 2011-03-29
PCT/EP2012/055660 WO2012130955A1 (en) 2011-03-29 2012-03-29 Prevention of hypoglycaemia in diabetes mellitus type 2 patients

Publications (2)

Publication Number Publication Date
MX2013011174A true MX2013011174A (es) 2013-11-01
MX336657B MX336657B (es) 2016-01-27

Family

ID=44504331

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013011174A MX336657B (es) 2011-03-29 2012-03-29 Prevencion de hipoglucemia en pacientes con diabetes sacarina de tipo 2.

Country Status (19)

Country Link
US (2) US20120277147A1 (es)
EP (1) EP2691109B1 (es)
JP (1) JP6410600B2 (es)
KR (1) KR20140033030A (es)
CN (1) CN103582491B (es)
AU (1) AU2012234180B2 (es)
BR (1) BR112013024973B1 (es)
CA (1) CA2830811A1 (es)
CY (1) CY1116799T1 (es)
DK (1) DK2691109T3 (es)
ES (1) ES2549955T3 (es)
HR (1) HRP20151087T1 (es)
HU (1) HUE025716T2 (es)
MX (1) MX336657B (es)
PL (1) PL2691109T3 (es)
PT (1) PT2691109E (es)
RU (1) RU2583134C2 (es)
SI (1) SI2691109T1 (es)
WO (1) WO2012130955A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2349324T3 (en) 2008-10-17 2017-12-11 Sanofi Aventis Deutschland COMBINATION OF AN INSULIN AND A GLP-1 AGONIST
KR101836070B1 (ko) 2009-11-13 2018-03-09 사노피-아벤티스 도이칠란트 게엠베하 Ｇｌｐ－１ 작용제, 인슐린 및 메티오닌을 포함하는 약제학적 조성물
ES2965209T3 (es) 2009-11-13 2024-04-11 Sanofi Aventis Deutschland Composición farmacéutica que comprende desPro36exendina-4(1-39)-Lys6-NH2 y metionina
CN103179978A (zh) 2010-08-30 2013-06-26 赛诺菲-安万特德国有限公司 Ave0010用于制造供治疗2型糖尿病用的药物的用途
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
ES2550357T3 (es) 2011-08-29 2015-11-06 Sanofi-Aventis Deutschland Gmbh Combinación farmacéutica para su uso en el control glucémico en pacientes de diabetes de tipo 2
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
TWI780236B (zh) 2013-02-04 2022-10-11 法商賽諾菲公司 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
CN114939156A (zh) 2014-01-09 2022-08-26 赛诺菲 门冬胰岛素的稳定化药物制剂
BR112016013832A2 (pt) 2014-01-09 2017-08-08 Sanofi Sa Uso de análogo e/ou derivado de insulina, formulação farmacêutica e processo para a preparação da mesma, kit e dispositivo médico
MX2016008979A (es) 2014-01-09 2016-10-04 Sanofi Sa Formulaciones farmaceuticas estabilizadas de analogos de insulina y/o derivados de insulina.
HRP20230470T1 (hr) 2014-12-12 2023-07-21 Sanofi-Aventis Deutschland Gmbh Formulacija fiksnog omjera inzulin glargin/liksisenatid
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
WO2020112253A2 (en) * 2018-10-16 2020-06-04 The Board Of Regents Of The University Of Oklahoma Uses of glucagon-like peptide-1 receptor agonists for treating trauma-induced hearing loss

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
CN1450902A (zh) * 1999-11-03 2003-10-22 布里斯托尔-迈尔斯斯奎布公司 包含二甲双胍和格列本脲组合的药用组合物
CN1413582A (zh) * 2002-11-29 2003-04-30 贵州圣济堂制药有限公司 盐酸二甲双胍肠溶片及其制备方法
ES2380556T3 (es) * 2005-06-27 2012-05-16 Newtree Co., Ltd. Métodos para prevenir y tratar estados mediados por PPAR usando macelignano.
AU2006292377B2 (en) * 2005-09-20 2011-03-03 Emisphere Technologies, Inc. Use of a DPP-IV inhibitor to reduce hypoglycemic events
DK2349324T3 (en) * 2008-10-17 2017-12-11 Sanofi Aventis Deutschland COMBINATION OF AN INSULIN AND A GLP-1 AGONIST

Also Published As

Publication number Publication date
US20120277147A1 (en) 2012-11-01
CN103582491B (zh) 2016-12-07
US20180000902A1 (en) 2018-01-04
AU2012234180B2 (en) 2017-02-16
HK1192725A1 (en) 2014-08-29
CN103582491A (zh) 2014-02-12
SI2691109T1 (sl) 2015-11-30
BR112013024973B1 (pt) 2022-06-07
HRP20151087T1 (hr) 2015-11-20
PL2691109T3 (pl) 2015-12-31
MX336657B (es) 2016-01-27
CA2830811A1 (en) 2012-10-04
PT2691109E (pt) 2015-10-30
AU2012234180A1 (en) 2013-10-17
CY1116799T1 (el) 2017-03-15
RU2583134C2 (ru) 2016-05-10
HUE025716T2 (en) 2016-04-28
EP2691109A1 (en) 2014-02-05
WO2012130955A1 (en) 2012-10-04
JP2014514289A (ja) 2014-06-19
RU2013148014A (ru) 2015-05-10
ES2549955T3 (es) 2015-11-03
BR112013024973A2 (pt) 2016-08-30
KR20140033030A (ko) 2014-03-17
JP6410600B2 (ja) 2018-10-24
EP2691109B1 (en) 2015-07-15
DK2691109T3 (en) 2015-10-19

Similar Documents

Publication Publication Date Title
MX2013011174A (es) Prevencion de hipoglucemia en pacientes con diabetes sacarina de tipo 2.
MX2013008484A (es) Prevencion de hidroglucemia en pacientes con diabetes mellitus tipo 2.
CY1113755T1 (el) Η λιξισενατιδη ως επιπροσθετη αγωγη στην ινσουλινη γλαργινη και στη μετφορμινη για τη θεραπευτικη αντιμετωπιση του διαβητη τυπου 2
MX339614B (es) Uso de ave0010 para la fabricacion de un medicamento para el tratamiento de la diabetes mellitus tipo 2.
AR099078A2 (es) Un medicamento que comprende acetato de glatiramer
IL192104A (en) Formulation suitable for subcutaneous administration containing molecules of ctla4ig, sugar and liquid liquid pharmacist acceptable and its use in drug preparation
WO2007098479A3 (en) Localized insulin delivery for bone healing
PE20142319A1 (es) Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
GEP201706719B (en) Pirfenidone treatment for patients with atypical liver function
MX362503B (es) Combinacion farmaceutica para mejorar el control glucemico como terapia adicional a la insulina basal.
PH12014500386A1 (en) Combination treatment for hepatitis c
AR086356A1 (es) Combinacion farmaceutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2
CY1117603T1 (el) Η λιξισενατιδη ως προσθετο στη μετφορμινη στην θεραπευτικη αγωγη του διαβητη τυπου 2
HK1206246A1 (en) Use of high dose laquinimod for treating multiple sclerosis
PH12017501662A1 (en) Treatment type 2 diabetes mellitus patients
EA201391689A1 (ru) Система доставки лекарственного средства
MX2009011900A (es) Curacion de herida diabetica.
PH12015500653B1 (en) Combination drug comprising gemigliptin and metformin, and method for the preparation thereof
WO2007133796A3 (en) Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist
MX341660B (es) Agonista del receptor de ghrelina para el tratamiento de caquexia.
NZ597675A (en) Medicament for the long term nsaid use
IL218069A (en) Oligoscride compounds, drug, pharmaceutical, and compound for its use in therapy
MY157671A (en) Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
NZ750752A (en) Treatment of fabry disease in ert-naïve and ert-experienced patients